Highlights Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Equities

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-01-13			5-day change	1st Jan Change
64.52 ^CNY	+1.05%		+2.32%	+8.31%

Jan. 12	Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug	MT
Jan. 12	Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation	MT

Highlights

Jan. 12	Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug	MT
Jan. 12	Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation	MT
Jan. 07	Hengrui Pharmaceuticals Wins China Marketing Approval for Gastric Cancer Drug	MT
Jan. 07	Jiangsu Hengrui Pharmaceuticals says unit got notice from NMPA for retlirafusp alfa injection	RE
Jan. 05	Hengrui Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Clinical Trials	MT
Jan. 05	Hengrui Pharmaceuticals Gets Approval for Combined Obesity Drug Trials	MT
Jan. 04	Tranche Update on Jiangsu Hengrui Pharmaceuticals Co.,Ltd's Equity Buyback Plan announced on August 20, 2025.	CI
Dec. 30	Hengrui Pharma Gets Nod to Trial Six Drugs	MT
Dec. 30	Hengrui Pharma Gets Nod to Trial HRS-6257 Tablets	MT
Dec. 28	Hengrui Pharmaceuticals Licenses Kidney Drug to Hansoh Pharma in Related-Party Deal	MT
Dec. 28	Jiangsu Hengrui Pharmaceuticals Co.,Ltd Enters into A License Agreement	CI
Dec. 15	Hengrui Medicine's Unit Gets Nod to Trial Tumor Drug	MT
Dec. 15	Hengrui Medicine's Unit Gets Nod to Trial RSS0343 Tablets	MT
Dec. 15	Hengrui Medicine's Unit Gets Nod to Trial HRS9531 Injection	MT
Dec. 08	Jiangsu Hengrui Medicine Gets Inclusion in China's Medical Insurance Catalog	MT
Dec. 02	Hengrui Medicine Gets Regulatory Acceptance for Anesthetic Marketing Application	MT
Nov. 27	Hengrui Medicine Gets China Approval for Multiple Drug Trials	MT
Nov. 27	Hengrui Medicine Gets Regulatory Nod for Vitiligo Drug Trials	MT
Nov. 25	Hengrui Medicine Gets Clinical Trial Approval for Tumor Monotherapy; Shares Up 3%	MT
Nov. 25	Hengrui Medicine Gets Clinical Trial Approval for Tumor Treatment	MT
Nov. 24	Hengrui Medicine Says Emavusitinib Marketing Application Accepted by Chinese Drug Regulator	MT
Nov. 24	Hengrui Medicine Gets Marketing Approval for Synthetic Vitamin D	MT
Nov. 23	Hengrui Pharmaceuticals Gets Clinical Trial Approval for Skin Disease Treatment	MT
Nov. 17	Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Nine Drug Candidates	MT
Nov. 17	Jiangsu Hengrui Medicine Gets China Clinical Trial Nod for Two Anti-Tumor Drugs	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Equities

600276

CNE0000014W7

Pharmaceuticals

Highlights

Filters